应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
SBHMY 中国生物制药ADR
休市中 12-05 10:41:46 EST 延时
资讯
新帖
简况
利好密集来袭！创新药概念大爆发
东方财富研究中心 · 10-31
利好密集来袭！创新药概念大爆发
中国生物制药(1177HK)：PDE3/4抑制剂II期临床数据亮眼 市场潜力巨大
招银国际 · 10-13
中国生物制药(1177HK)：PDE3/4抑制剂II期临床数据亮眼 市场潜力巨大
大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权
保观 · 09-29
大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权
华源证券-医药行业周报信立泰：全面布局CKM管线，创新出海加速推进-250928
新浪财经 · 09-28
华源证券-医药行业周报信立泰：全面布局CKM管线，创新出海加速推进-250928
中国生物制药：TQB3122“PARP1抑制剂”临床试验申请获NMPA受理
东方财富 · 08-11
中国生物制药：TQB3122“PARP1抑制剂”临床试验申请获NMPA受理
中国生物制药下跌4.48%，报7.03元/股
金融界 · 08-11
中国生物制药下跌4.48%，报7.03元/股
中国生物制药8月7日成交额为131.00美元
市场透视 · 08-08
中国生物制药8月7日成交额为131.00美元
中国生物制药下跌2.93%，报7.28元/股
金融界 · 08-07
中国生物制药下跌2.93%，报7.28元/股
中国生物制药：罗伐昔替尼Ⅲ期试验正招募受试者
和讯网 · 08-06
中国生物制药：罗伐昔替尼Ⅲ期试验正招募受试者
中国生物制药8月5日成交额为261.00美元
市场透视 · 08-06
中国生物制药8月5日成交额为261.00美元
中国生物制药：TQC3302“ICS/LAMA/LABA软雾吸入制剂”临床试验申请获NMPA批准
动脉网 · 08-05
中国生物制药：TQC3302“ICS/LAMA/LABA软雾吸入制剂”临床试验申请获NMPA批准
生物药集采将落地？近300亿元规模市场即将迎来新一轮洗牌
制药网 · 08-04
生物药集采将落地？近300亿元规模市场即将迎来新一轮洗牌
中金医药8月组合：看好创新药及产业链 关注政策端积极变化
中金公司 · 08-04
中金医药8月组合：看好创新药及产业链 关注政策端积极变化
中国生物制药拟8月18日举行董事会会议批准中期业绩
格隆汇资讯 · 08-01
中国生物制药拟8月18日举行董事会会议批准中期业绩
中国生物制药：董事会召开通知
香港交易所 · 08-01
中国生物制药：董事会召开通知
中证沪港深500医药卫生指数下跌1.74%，前十大权重包含恒瑞医药等
金融界 · 08-01
中证沪港深500医药卫生指数下跌1.74%，前十大权重包含恒瑞医药等
中国生物制药7月31日成交额为4.01万美元
市场透视 · 08-01
中国生物制药7月31日成交额为4.01万美元
中国生物制药(1177.HK)：创新管线价值重估 制药龙头华丽转身
招银国际 · 07-31
中国生物制药(1177.HK)：创新管线价值重估 制药龙头华丽转身
中国生物制药7月29日成交额为149.00美元
市场透视 · 07-30
中国生物制药7月29日成交额为149.00美元
医药行业行业研究：慢阻肺专题深度：慢病蓝海疗法迭代，国产新药BD潜力凸显
国金证券 · 07-30
医药行业行业研究：慢阻肺专题深度：慢病蓝海疗法迭代，国产新药BD潜力凸显
加载更多
公司概况
公司名称：
中国生物制药ADR
所属市场：
PINK LIMITED
上市日期：
--
主营业务：
中国生物制药有限公司是一间主要从事药品业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部主要从事长期及短期投资。其他分部主要从事相关医疗及医院业务。
发行价格：
--
{"stockData":{"symbol":"SBHMY","market":"US","secType":"STK","nameCN":"中国生物制药ADR","latestPrice":18.22,"timestamp":1764949306151,"preClose":18.22,"halted":0,"volume":3,"delay":15,"floatShares":457950931,"shares":910273459,"eps":0.524054,"marketStatus":"休市中","change":0,"latestTime":"12-05 10:41:46 EST 延时","open":18.22,"high":18.22,"low":18.22,"amount":52.724999999999994,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.524054,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":20,"exchange":"PINK LIMITED","adjPreClose":18.22,"volumeRatio":0.023622049104098354},"requestUrl":"/m/hq/s/SBHMY","defaultTab":"news","newsList":[{"id":"2579462065","title":"利好密集来袭！创新药概念大爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2579462065","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579462065?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:54","pubTimestamp":1761904444,"startTime":"0","endTime":"0","summary":"据证券时报报道，今年国家医保谈判在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。此外，年内国产创新药“出海”进程明显提速。根据医药魔方NextPharma数据库，截至10月21日，中国创新药今年对外许可共发生115起，金额总计达到1012.4亿美元，远超2024年全年的519亿美元。国信证券指出，中国创新药产业已经体现出长期向好的发展趋势，并在近年集中体现在BD交易的爆发式增长。配置上，看好创新药长期逻辑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180526a47fc459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180526a47fc459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","01952","SBHMY","BK4007","09995","02552","06990"],"gpt_icon":0},{"id":"2575288909","title":"中国生物制药(1177HK)：PDE3/4抑制剂II期临床数据亮眼 市场潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2575288909","media":"招银国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575288909?lang=zh_cn&edition=full","pubTime":"2025-10-13 00:00","pubTimestamp":1760284800,"startTime":"0","endTime":"0","summary":"中国生物制药在欧洲呼吸学会2025 年会上公布了其PDE3/4 抑制剂TQC3721 的II 期临床结果，临床结果显示TQC3721 可快速改善患者肺功能和症状。临床数据表明TQC3721 具备同类最佳潜力。PDE3/4 药物市场潜力巨大，竞争格局良好。默沙东在今年7 月宣布以100 亿美元收购Verona，体现PDE3/4 抑制剂巨大的市场潜力。作为全球进度第二且唯一处在III 期临床的PDE3/4 抑制剂，我们认为TQC3721 具备重磅海外授权潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101310413494c5896a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101310413494c5896a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2571800933","title":"大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2571800933","media":"保观","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571800933?lang=zh_cn&edition=full","pubTime":"2025-09-29 12:04","pubTimestamp":1759118650,"startTime":"0","endTime":"0","summary":"保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","LU1226288170.HKD","LU1023057109.AUD","BK1593","LU1152091168.USD","01093","LU2328871848.SGD","01276","LU1008478684.HKD","LU1152091754.HKD","BK1515","00874","LU1303224171.USD","IE00B543WZ88.USD","03692","LU1969619763.USD","02196","LU1960683339.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0072913022.USD","BK1191","LU1226287529.USD","03320","IE00B031HY20.USD","LU2039709279.SGD","LU2543165471.USD","LU0359201885.HKD","BK1606","00570","06160","SBHMY","LU1719994722.HKD","LU1993786604.SGD","BK1500","LU0588546209.SGD","LU0067412154.USD","BK1197","LU1226287875.USD","01177","LU1226287792.SGD","LU1251922891.USD","03933","IE00BZ08YR35.GBP","IE0008368742.USD","LU1328277881.USD","BK1570","SG9999004220.SGD","LU1226288253.USD","IE0008369823.USD","LU0315179316.USD"],"gpt_icon":0},{"id":"2571782687","title":"华源证券-医药行业周报信立泰：全面布局CKM管线，创新出海加速推进-250928","url":"https://stock-news.laohu8.com/highlight/detail?id=2571782687","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571782687?lang=zh_cn&edition=full","pubTime":"2025-09-28 23:02","pubTimestamp":1759071720,"startTime":"0","endTime":"0","summary":"全面布局CKM管线，创新出海加速推进。我们认为信立泰创新研发已经迎来重大蜕变，公司全面布局心血管-肾脏-代谢慢病领域，在研管线涵盖高血压、血脂异常、心衰、代谢、肾科等多个领域，并布局单抗、多抗、ADC、多肽、环肽、基因编辑等新型技术平台，多款产品已经进入到临床阶段，不断强化公司在中国慢病领域综合性龙头地位。我们看好信立泰基于心血管为核心的CKM创新管线布局，带动公司成长为中国综合性慢病领域创新药龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092900142997af3c80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092900142997af3c80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","IE00BZ08YS42.EUR","LU1008478684.HKD","LU1993786604.SGD","LU1152091754.HKD","01276","SBHMY","LU1226287792.SGD","BK1161","BK1521","LU1023057109.AUD","LU1807302812.USD","LU1951186391.HKD","IE00B031HY20.USD","LU2039709279.SGD","IE00BZ08YT58.USD","LU1152091168.USD","LU0359202008.SGD","BK1191","LU1226288170.HKD","LU0315179316.USD","03692","LU1328277881.USD","IE00BZ08YR35.GBP","09926","LU0359201612.USD","LU1813983027.USD","LU0314109678.HKD","BK1589","LU1226287529.USD","LU0880133367.SGD","LU0072913022.USD","BK1583","LU0326950275.SGD","LU0359201885.HKD","IE00B543WZ88.USD","IE0008369823.USD","IE00B5MMRT66.SGD","IE0008368742.USD","BK1515","LU1960683339.HKD","06978","LU1226288253.USD","BK1574","LU2543165471.USD","LU1226287875.USD","LU0501845795.SGD","LU0067412154.USD","SG9999004220.SGD","LU0140636845.USD","01177"],"gpt_icon":0},{"id":"2558866382","title":"中国生物制药：TQB3122“PARP1抑制剂”临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2558866382","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558866382?lang=zh_cn&edition=full","pubTime":"2025-08-11 20:37","pubTimestamp":1754915832,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)公布，该集团自主研发的创新药TQB3122“PARP1抑...中国生物制药(01177)公布，该集团自主研发的创新药TQB3122“PARP1抑制剂”的新药临床试验申请(IND)已获得中国国家药品监督管理局 (NMPA)受理，拟用于治疗晚期恶性肿瘤。TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂，通过双重机制发挥抗肿瘤作用：一方面，竞争性抑制PARP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811204201a4820139&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811204201a4820139&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2558563369","title":"中国生物制药下跌4.48%，报7.03元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558563369","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558563369?lang=zh_cn&edition=full","pubTime":"2025-08-11 10:17","pubTimestamp":1754878639,"startTime":"0","endTime":"0","summary":"8月11日，中国生物制药盘中下跌4.48%，截至10:10，报7.03元/股，成交3.03亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。8月18日，中国生物制药将披露2025财年中报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811102138a480fc19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811102138a480fc19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK1191","IE00BZ08YS42.EUR","BK1521","BK1589","BK1515","01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2557548550","title":"中国生物制药8月7日成交额为131.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557548550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557548550?lang=zh_cn&edition=full","pubTime":"2025-08-08 13:59","pubTimestamp":1754632778,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，中国生物制药成交额为131.00美元，当日成交量为7.00股。中国生物制药于2025年8月7日涨0.0%，报18.65美元，该股过去5个交易日涨0.0%，年初至今涨126.39%，过去60日涨98.87%。中国采用先进的现代化中国和生物医学技术，以研究，开发，制造和销售各种中药和化学药品。该公司的产品可分为肝炎和心脑血管疾病这两大治疗类别。该公司通过国际伙伴关系积极寻求合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808135946a47c8373&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808135946a47c8373&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY"],"gpt_icon":0},{"id":"2557827315","title":"中国生物制药下跌2.93%，报7.28元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557827315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557827315?lang=zh_cn&edition=full","pubTime":"2025-08-07 10:34","pubTimestamp":1754534070,"startTime":"0","endTime":"0","summary":"8月7日，中国生物制药盘中下跌2.93%，截至10:21，报7.28元/股，成交3.01亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。8月18日，中国生物制药将披露2025财年中报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080710395794d4a632&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080710395794d4a632&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1191","BK1521","IE00BZ08YT58.USD","SBHMY","01177","BK1515","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2557547374","title":"中国生物制药：罗伐昔替尼Ⅲ期试验正招募受试者","url":"https://stock-news.laohu8.com/highlight/detail?id=2557547374","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557547374?lang=zh_cn&edition=full","pubTime":"2025-08-06 18:42","pubTimestamp":1754476965,"startTime":"0","endTime":"0","summary":"【8月6日中国生物制药罗伐昔替尼Ⅲ期临床试验启动受试者招募】8月6日，中国生物制药公告透露，罗伐昔替尼用于治疗中重度cGVHD的Ⅲ期临床试验，目前正处于受试者招募阶段。该集团表示，将加快罗伐昔替尼的全球临床开发进程，以便尽早为全球患者提供更优质的治疗方案。本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806200217973763eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806200217973763eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","SBHMY","01177","BK1589","IE00BZ08YT58.USD","BK1521","BK1191","IE00BZ08YS42.EUR","BK1515"],"gpt_icon":0},{"id":"2557340249","title":"中国生物制药8月5日成交额为261.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557340249","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557340249?lang=zh_cn&edition=full","pubTime":"2025-08-06 13:47","pubTimestamp":1754459258,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，中国生物制药成交额为261.00美元，当日成交量为14.00股。中国生物制药于2025年8月5日涨0.0%，报18.65美元，该股过去5个交易日涨0.0%，年初至今涨126.39%，过去60日涨98.87%。中国采用先进的现代化中国和生物医学技术，以研究，开发，制造和销售各种中药和化学药品。该公司的产品可分为肝炎和心脑血管疾病这两大治疗类别。该公司通过国际伙伴关系积极寻求合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806134745a477ff67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806134745a477ff67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2557398457","title":"中国生物制药：TQC3302“ICS/LAMA/LABA软雾吸入制剂”临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2557398457","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557398457?lang=zh_cn&edition=full","pubTime":"2025-08-05 18:44","pubTimestamp":1754390640,"startTime":"0","endTime":"0","summary":"中国生物制药的TQC3302“ICS/LAMA/LABA软雾吸入制剂”获NMPA临床试验批准，用于慢性阻塞性肺疾病治疗。该制剂为全球首款三联复方软雾吸入剂，有望为患者提供更多治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080518512494d10f01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080518512494d10f01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2556746448","title":"生物药集采将落地？近300亿元规模市场即将迎来新一轮洗牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2556746448","media":"制药网","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556746448?lang=zh_cn&edition=full","pubTime":"2025-08-04 10:51","pubTimestamp":1754275889,"startTime":"0","endTime":"0","summary":"即便在生物类似药上市后，价格战已使年治疗费降至3万元以下，但对于需长期用药的类风湿关节炎患者而言，仍是不小的负担。中国生物制药2024年研发投入54.9亿元，其中77%投向创新药，全年获批4个国家1类创新药，展现了从生物类似药向原研创新的转型努力。按300亿元市场规模和48%的降幅计算，集采可节省约144亿元医保支出，这些资金将可能投向CAR-T等创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508041052159731b4df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508041052159731b4df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","02696","01177","BK4007"],"gpt_icon":0},{"id":"2556386180","title":"中金医药8月组合：看好创新药及产业链 关注政策端积极变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2556386180","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556386180?lang=zh_cn&edition=full","pubTime":"2025-08-04 00:00","pubTimestamp":1754236800,"startTime":"0","endTime":"0","summary":"评论看好创新药长期产业发展趋势。关注创新产业链。受益于年初以来以港股18A为代表的创新药行业繁荣，目前一二级市场投融资一改过去3-4 年的颓势，二季度开始出现较为明显的反转。此外以药明康德为代表的CDMO近期亮眼的中报业绩，体现创新药供应链体系在全球经济不确定性下的经营韧性。期待内需相关政策的积极影响。估值与建议A股：百济神州、恒瑞医药、科伦药业、泰格医药、药明康德、新产业、华大智造、惠泰医疗、迪安诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804193156a4745b04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804193156a4745b04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","LU1115378108.SGD","688617","ONC","ZLAB","SHTDY","09926","SBHMY","01099","688235","03347","09688","02219","06990","01093","06160","BK1515","BK1574","WXIBF","02005","BK1500","09939","LU0640798160.USD","06978","603259","03759","BK1161","00512","688114","BK1197","02269"],"gpt_icon":0},{"id":"2556895545","title":"中国生物制药拟8月18日举行董事会会议批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2556895545","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556895545?lang=zh_cn&edition=full","pubTime":"2025-08-01 16:55","pubTimestamp":1754038528,"startTime":"0","endTime":"0","summary":"格隆汇8月1日丨中国生物制药(01177.HK)宣布，公司将于2025年8月18日（星期一）举行董事会会议，藉以批准（其中包括）刊发公司及其附属公司截至2025年6月30日止六个月期间的未经审核中期业绩，以及考虑派发中期股息（如有）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801165552972c7486&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801165552972c7486&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","BK1589","SBHMY","BK1515","01177","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2556489733","title":"中国生物制药：董事会召开通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2556489733","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556489733?lang=zh_cn&edition=full","pubTime":"2025-08-01 16:40","pubTimestamp":1754037609,"startTime":"0","endTime":"0","summary":"公司董事会现由六位执行董事及五位独立非执行董事组成，执行董事包括谢其润女士、谢炳先生、郑翔玲女士、谢承润先生、谢炘先生及田舟山先生；独立非执行董事包括陆正飞先生、李大魁先生、鲁红女士、张鲁夫先生及李国栋医生。中国生物制药宣布，将于2025年8月18日（星期一）召开董事会会议，主要议程包括审议及批准截至2025年6月30日止六个月期间之未经审核中期业绩，同时将考虑派发中期股息事宜。该公告为独立文件：","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801183154972ca3a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801183154972ca3a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY","01177"],"gpt_icon":1},{"id":"2556586095","title":"中证沪港深500医药卫生指数下跌1.74%，前十大权重包含恒瑞医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2556586095","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556586095?lang=zh_cn&edition=full","pubTime":"2025-08-01 15:48","pubTimestamp":1754034492,"startTime":"0","endTime":"0","summary":"数据统计显示，中证沪港深500医药卫生指数近一个月上涨17.84%，近三个月上涨24.27%，年至今上涨34.48%。从中证沪港深500医药卫生指数持仓的市场板块来看，香港证券交易所占比37.87%、上海证券交易所占比33.61%、深圳证券交易所占比28.52%。从中证沪港深500医药卫生指数持仓样本的行业来看，化学药占比36.20%、制药与生物科技服务占比18.33%、生物药品占比18.14%、医疗器械占比11.07%、中药占比8.56%、医疗商业与服务占比7.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080115594994c860b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080115594994c860b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603259","01093","WXIBF","688271","01801","02269","688235","01177","600276","BK1191","01276","ONC","09926","SBHMY","06160","02359"],"gpt_icon":1},{"id":"2556861707","title":"中国生物制药7月31日成交额为4.01万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556861707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556861707?lang=zh_cn&edition=full","pubTime":"2025-08-01 13:58","pubTimestamp":1754027898,"startTime":"0","endTime":"0","summary":"美东时间2025年7月31日，中国生物制药成交额为4.01万美元，当日成交量为2149.00股。中国生物制药于2025年7月31日涨0.0%，报18.65美元，该股过去5个交易日涨14.42%，年初至今涨126.39%，过去60日涨98.87%。中国采用先进的现代化中国和生物医学技术，以研究，开发，制造和销售各种中药和化学药品。该公司的产品可分为肝炎和心脑血管疾病这两大治疗类别。它还积极开发治疗肿瘤，糖尿病和其他疾病的药物。该公司通过国际伙伴关系积极寻求合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801135820a46f086a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801135820a46f086a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY"],"gpt_icon":0},{"id":"2555885706","title":"中国生物制药(1177.HK)：创新管线价值重估 制药龙头华丽转身","url":"https://stock-news.laohu8.com/highlight/detail?id=2555885706","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555885706?lang=zh_cn&edition=full","pubTime":"2025-07-31 00:00","pubTimestamp":1753891200,"startTime":"0","endTime":"0","summary":"作为领先的中国制药企业，中国生物制药的创新转型已取得显著成果。截至2024 年末，公司累计获批创新药物 已达17 款，创新产品收入占比在2024 年已达到42%。创新药迎来收获期。生物类似药快速增长，化学仿制药业务保持稳健。考虑到中国生物制药在国内的成熟销售网络，我们预计其生物类似药销售有望快速放量，特别是首仿帕妥珠单抗。首次覆盖给予“买入”评级，目标价9.40 港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731165631a46d2f7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731165631a46d2f7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY","01177"],"gpt_icon":0},{"id":"2555404090","title":"中国生物制药7月29日成交额为149.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555404090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555404090?lang=zh_cn&edition=full","pubTime":"2025-07-30 14:03","pubTimestamp":1753855426,"startTime":"0","endTime":"0","summary":"美东时间2025年7月29日，中国生物制药成交额为149.00美元，成交额较昨日减少99.22%，当日成交量为8.00股。中国生物制药于2025年7月29日涨0.0%，报18.65美元，该股过去5个交易日涨14.42%，年初至今涨126.39%，过去60日涨98.87%。中国采用先进的现代化中国和生物医学技术，以研究，开发，制造和销售各种中药和化学药品。该公司的产品可分为肝炎和心脑血管疾病这两大治疗类别。它还积极开发治疗肿瘤，糖尿病和其他疾病的药物。该公司通过国际伙伴关系积极寻求合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730140355a46aed98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730140355a46aed98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY"],"gpt_icon":0},{"id":"2555099114","title":"医药行业行业研究：慢阻肺专题深度：慢病蓝海疗法迭代，国产新药BD潜力凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2555099114","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555099114?lang=zh_cn&edition=full","pubTime":"2025-07-30 11:35","pubTimestamp":1753846542,"startTime":"0","endTime":"0","summary":"投资逻辑慢阻肺疾病负担沉重，亟待更优治疗方案。慢阻肺主要通过药物进行治疗，以预防及控制慢性炎症并减轻临床症状，2022年我国慢阻肺药物市场规模已超过30亿美元。慢阻肺长期治疗药物包括皮质类固醇、长效支气管扩张剂及抗炎药物，真实世界研究结果显示，多数患者在接受目前标准疗法治疗后仍控制不佳，临床亟需寻求更为优化治疗方案，以及更为创新的治疗手段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073011354894c2f13a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073011354894c2f13a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","01177","600276","01276"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.1201},{"period":"1month","weight":-0.0113},{"period":"3month","weight":0.2931},{"period":"6month","weight":0.5235},{"period":"1year","weight":0.6487},{"period":"ytd","weight":1.1867}],"description":"中国生物制药有限公司是一间主要从事药品业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部主要从事长期及短期投资。其他分部主要从事相关医疗及医院业务。","exchange":"PINK LIMITED","name":"中国生物制药ADR","nameEN":"Sino Biopharmaceutical Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药ADR(SBHMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药ADR(SBHMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药ADR,SBHMY,中国生物制药ADR股票,中国生物制药ADR股票老虎,中国生物制药ADR股票老虎国际,中国生物制药ADR行情,中国生物制药ADR股票行情,中国生物制药ADR股价,中国生物制药ADR股市,中国生物制药ADR股票价格,中国生物制药ADR股票交易,中国生物制药ADR股票购买,中国生物制药ADR股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药ADR(SBHMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药ADR(SBHMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}